DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,778,075 | -3.1% | 67,626 | -6.3% | 0.37% | +17.6% |
| Q2 2023 | $17,314,388 | -22.3% | 72,143 | -18.4% | 0.31% | +0.3% |
| Q1 2023 | $22,294,217 | -15.3% | 88,455 | -10.8% | 0.31% | -12.1% |
| Q4 2022 | $26,307,445 | +0.2% | 99,116 | -2.5% | 0.36% | -7.6% |
| Q3 2022 | $26,266,000 | +4.0% | 101,689 | +2.1% | 0.38% | -1.3% |
| Q2 2022 | $25,262,000 | -14.8% | 99,645 | -1.4% | 0.39% | -2.0% |
| Q1 2022 | $29,647,000 | -18.0% | 101,071 | -8.1% | 0.40% | -33.1% |
| Q4 2021 | $36,171,000 | +5.6% | 109,941 | -2.3% | 0.59% | +34.8% |
| Q3 2021 | $34,268,000 | -4.2% | 112,560 | -15.5% | 0.44% | -2.9% |
| Q2 2021 | $35,760,000 | +23.1% | 133,251 | +3.3% | 0.45% | +11.9% |
| Q1 2021 | $29,045,000 | -3.0% | 129,043 | -4.2% | 0.40% | -7.7% |
| Q4 2020 | $29,933,000 | +3.9% | 134,750 | +0.7% | 0.44% | -7.6% |
| Q3 2020 | $28,805,000 | +25.1% | 133,769 | +2.7% | 0.48% | +11.0% |
| Q2 2020 | $23,030,000 | +26.8% | 130,237 | -0.7% | 0.43% | -2.9% |
| Q1 2020 | $18,156,000 | -13.2% | 131,178 | -3.7% | 0.44% | +15.7% |
| Q4 2019 | $20,911,000 | +4.2% | 136,249 | -1.9% | 0.38% | -4.5% |
| Q3 2019 | $20,067,000 | -4.4% | 138,940 | -5.4% | 0.40% | -43.4% |
| Q2 2019 | $20,983,000 | -1.6% | 146,815 | -9.1% | 0.70% | -16.3% |
| Q1 2019 | $21,318,000 | +23.5% | 161,475 | -3.6% | 0.84% | +14.2% |
| Q4 2018 | $17,265,000 | -3.7% | 167,428 | +1.5% | 0.74% | +16.2% |
| Q3 2018 | $17,931,000 | +6.1% | 165,018 | -3.6% | 0.63% | -2.2% |
| Q2 2018 | $16,893,000 | -8.5% | 171,195 | -9.2% | 0.65% | -8.5% |
| Q1 2018 | $18,463,000 | +3.6% | 188,565 | -1.7% | 0.71% | +5.7% |
| Q4 2017 | $17,814,000 | +7.9% | 191,922 | -0.3% | 0.67% | +5.5% |
| Q3 2017 | $16,511,000 | +0.9% | 192,487 | -0.7% | 0.64% | -1.1% |
| Q2 2017 | $16,359,000 | -2.8% | 193,848 | -1.5% | 0.64% | -4.2% |
| Q1 2017 | $16,826,000 | +10.7% | 196,718 | +0.7% | 0.67% | +6.5% |
| Q4 2016 | $15,204,000 | -10.8% | 195,318 | -10.2% | 0.63% | -9.2% |
| Q3 2016 | $17,052,000 | -18.3% | 217,534 | +5.3% | 0.69% | -18.6% |
| Q2 2016 | $20,865,000 | +5.2% | 206,588 | -1.2% | 0.85% | +5.5% |
| Q1 2016 | $19,831,000 | +4.7% | 209,052 | +2.5% | 0.81% | +8.0% |
| Q4 2015 | $18,947,000 | +7.7% | 203,997 | -1.2% | 0.75% | +9.5% |
| Q3 2015 | $17,600,000 | -7.8% | 206,560 | -7.4% | 0.68% | +7.9% |
| Q2 2015 | $19,089,000 | -1.5% | 223,027 | -2.3% | 0.63% | +1.0% |
| Q1 2015 | $19,377,000 | +1.9% | 228,230 | +2.9% | 0.63% | +1.8% |
| Q4 2014 | $19,017,000 | – | 221,875 | – | 0.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |